Residual proliferation in 7 donor-patient pairs
. | Responder . | . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stimulator . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | Mean ± SD . | ||||||
| Allo-PBMCs | 0 | 14.8 | 0 | 27.4 | 0 | 17.4 | 0 | 8.5 ± 11.3 | ||||||
| Allo-LCLs | 4.8 | 0 | 0.7 | 0 | 0 | 0 | 0 | 0.8 ± 1.8 | ||||||
. | Responder . | . | . | . | . | . | . | . | ||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Stimulator . | 1 . | 2 . | 3 . | 4 . | 5 . | 6 . | 7 . | Mean ± SD . | ||||||
| Allo-PBMCs | 0 | 14.8 | 0 | 27.4 | 0 | 17.4 | 0 | 8.5 ± 11.3 | ||||||
| Allo-LCLs | 4.8 | 0 | 0.7 | 0 | 0 | 0 | 0 | 0.8 ± 1.8 | ||||||
Residual proliferation in 7 donor-patient pairs after allodepletion with anti-CD25 immunotoxin following stimulation of donor PBMCs with PBMCs (R/S 1:1) or LCLs (R/S 40:1) from the same HLA-mismatched recipient. Residual proliferation was calculated using the formula in “Results” and was significantly higher after stimulation with PBMCs (P < .05).